In this open-label trial, a higher proportion of asymptomatic follicular lymphoma patients assigned to rituximab required no further treatment at nearly 15 years compared with those assigned to ...

SAN DIEGO -- The combination of loncastuximab tesirine (Zynlonta) and rituximab achieved promising response rates in patients with relapsed or refractory follicular lymphoma (R/R FL), according to a ...

A new statistical analysis of patients with follicular lymphoma, made possible by 15 years of follow-up data from a SWOG and ...

A Steuben County man has been cancer-free for two decades following treatment through a clinical trial at the University of Rochester Medical Center’s Wilmot Cancer Institute, where new research shows ...

Combination tafasitamab, lenalidomide, and rituximab is a recommended second-line regimen based on the phase 3 InMIND trial. The clinical data supporting the addition of tafasitamab to lenalidomide ...

Unlike some other forms of lymphoma, advanced stage follicular lymphoma is considered incurable. But a new analysis of ...

Epcoritamab plus rituximab/lenalidomide significantly improved PFS and ORR compared with rituximab/lenalidomide alone. The Food and Drug Administration (FDA) has approved Epkinly ® (epcoritamab-bysp), ...

Glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) is superior to rituximab (R)-GemOx for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), according to a study presented at ...

The watchful waiting approach defers chemotherapy, on average, for about 2.5 years. This time was significantly increased in the new study in patients on rituximab — the median time to initiation of ...

This open-label phase I study enrolled patients 18 years or older with newly diagnosed DLBCL. The first cohort (n = 6) received intravenous rituximab plus CHOP. This cohort received sqR for subsequent ...

Between June 1998 and August 2002, 114 patients who had received previous chemotherapy for indolent non-Hodgkin's lymphoma were treated with a standard 4-week course of rituximab. Patients with ...